POINT: POINT's prostate cancer trial meets primary endpoint as Lilly's offer looms
The topline data announcement comes on the same day as Lilly further extends its tender offer for the acquisition of POINT.
Read full article »
POINT is an Indiana-based radiopharmaceutical company that develops and commercializes radioligands for the treatment of cancer.
Read more